36% to 50% of patients progress to end-stage renal disease within 10 years.[1] The fluorescence intensity of C3 in pathology is inversely proportional to the prognosis of C3G.[3] Generally speaking, the prognosis of C3GN is better than that of DDD. Here, C3 is linked to stage 5 chronic kidney disease.